Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 37

1.

Endothelial impairment and bone marrow-derived CD34(+)/133(+) cells in diabetic patients with erectile dysfunction.

Murata M, Tamemoto H, Otani T, Jinbo S, Ikeda N, Kawakami M, Ishikawa SE.

J Diabetes Investig. 2012 Dec 20;3(6):526-33. doi: 10.1111/j.2040-1124.2012.00230.x. Epub 2012 Jul 24.

2.

Report of the committee on the classification and diagnostic criteria of diabetes mellitus.

Committee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus., Seino Y, Nanjo K, Tajima N, Kadowaki T, Kashiwagi A, Araki E, Ito C, Inagaki N, Iwamoto Y, Kasuga M, Hanafusa T, Haneda M, Ueki K.

J Diabetes Investig. 2010 Oct 19;1(5):212-28. doi: 10.1111/j.2040-1124.2010.00074.x.

3.

Osteoprotegerin predicts long-term outcome in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention.

Pedersen S, Mogelvang R, Bjerre M, Frystyk J, Flyvbjerg A, Galatius S, Sørensen TB, Iversen A, Hvelplund A, Jensen JS.

Cardiology. 2012;123(1):31-8. doi: 10.1159/000339880. Epub 2012 Sep 7.

4.

Prevalence and progression of peripheral vascular calcification in type 2 diabetes subjects with preserved kidney function.

Singh DK, Winocour P, Summerhayes B, Kaniyur S, Viljoen A, Sivakumar G, Farrington K.

Diabetes Res Clin Pract. 2012 Jul;97(1):158-65. doi: 10.1016/j.diabres.2012.01.038. Epub 2012 Mar 3.

PMID:
22386825
5.

Plasma osteoprotegerin is related to carotid and peripheral arterial disease, but not to myocardial ischemia in type 2 diabetes mellitus.

Poulsen MK, Nybo M, Dahl J, Hosbond S, Poulsen TS, Johansen A, Høilund-Carlsen PF, Beck-Nielsen H, Rasmussen LM, Henriksen JE.

Cardiovasc Diabetol. 2011 Aug 12;10:76. doi: 10.1186/1475-2840-10-76.

6.

Osteoprotegerin and coronary artery disease in type 2 diabetic patients with microalbuminuria.

Reinhard H, Nybo M, Hansen PR, Wiinberg N, Kjær A, Petersen CL, Winther K, Parving HH, Rasmussen LM, Rossing P, Jacobsen PK.

Cardiovasc Diabetol. 2011 Jul 29;10:70. doi: 10.1186/1475-2840-10-70.

7.

Association of plasma osteoprotegerin and adiponectin with arterial function, cardiac function and metabolism in asymptomatic type 2 diabetic men.

Chen WJ, Rijzewijk LJ, van der Meer RW, Heymans MW, van Duinkerken E, Lubberink M, Lammertsma AA, Lamb HJ, de Roos A, Romijn JA, Smit JW, Bax JJ, Bjerre M, Frystyk J, Flyvbjerg A, Diamant M.

Cardiovasc Diabetol. 2011 Jul 19;10:67. doi: 10.1186/1475-2840-10-67.

8.

Estrogen inhibits vascular calcification via vascular RANKL system: common mechanism of osteoporosis and vascular calcification.

Osako MK, Nakagami H, Koibuchi N, Shimizu H, Nakagami F, Koriyama H, Shimamura M, Miyake T, Rakugi H, Morishita R.

Circ Res. 2010 Aug 20;107(4):466-75. doi: 10.1161/CIRCRESAHA.110.216846. Epub 2010 Jul 1.

9.

The bone-vascular axis in chronic kidney disease.

Demer L, Tintut Y.

Curr Opin Nephrol Hypertens. 2010 Jul;19(4):349-53. doi: 10.1097/MNH.0b013e32833a3d67. Review.

10.

Plaque characterization of non-culprit lesions by virtual histology intravascular ultrasound in diabetic patients: impact of renal function.

Ogita M, Funayama H, Nakamura T, Sakakura K, Sugawara Y, Kubo N, Ako J, Ishikawa SE, Momomura S.

J Cardiol. 2009 Aug;54(1):59-65. doi: 10.1016/j.jjcc.2009.03.008. Epub 2009 May 21.

11.
12.

Relationship between circulating FGF23 and total body atherosclerosis in the community.

Mirza MA, Hansen T, Johansson L, Ahlström H, Larsson A, Lind L, Larsson TE.

Nephrol Dial Transplant. 2009 Oct;24(10):3125-31. doi: 10.1093/ndt/gfp205. Epub 2009 May 9.

PMID:
19429932
13.

Pathogenesis of diabetic macro- and microangiopathy.

Gärtner V, Eigentler TK.

Clin Nephrol. 2008 Jul;70(1):1-9. Review.

PMID:
18793542
14.

Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice.

Morony S, Tintut Y, Zhang Z, Cattley RC, Van G, Dwyer D, Stolina M, Kostenuik PJ, Demer LL.

Circulation. 2008 Jan 22;117(3):411-20. doi: 10.1161/CIRCULATIONAHA.107.707380. Epub 2008 Jan 2.

15.

Role of hyperphosphatemia and 1,25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice.

Stubbs JR, Liu S, Tang W, Zhou J, Wang Y, Yao X, Quarles LD.

J Am Soc Nephrol. 2007 Jul;18(7):2116-24. Epub 2007 Jun 6.

16.

Macroangiopathy in adults and children with diabetes: from molecular mechanisms to vascular damage (part 1).

Di Marzio D, Mohn A, Mokini ZH, Giannini C, Chiarelli F.

Horm Metab Res. 2006 Nov;38(11):691-705. Review.

PMID:
17111296
17.

Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway.

Luo XH, Guo LJ, Xie H, Yuan LQ, Wu XP, Zhou HD, Liao EY.

J Bone Miner Res. 2006 Oct;21(10):1648-56.

18.

Circulating osteoprotegerin is correlated with lipid profile, insulin sensitivity, adiponectin and sex steroids in an ageing male population.

Gannagé-Yared MH, Fares F, Semaan M, Khalife S, Jambart S.

Clin Endocrinol (Oxf). 2006 Jun;64(6):652-8.

PMID:
16712667
19.

The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects.

Anand DV, Lahiri A, Lim E, Hopkins D, Corder R.

J Am Coll Cardiol. 2006 May 2;47(9):1850-7. Epub 2006 Apr 19.

20.

Pathogenesis of vascular calcification in dialysis patients.

Ketteler M, Westenfeld R, Schlieper G, Brandenburg V.

Clin Exp Nephrol. 2005 Dec;9(4):265-70. Review.

PMID:
16362152

Supplemental Content

Support Center